8-K 1 doc1.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2003 --------------------------- CALYPTE BIOMEDICAL CORPORATION. Exact name of Registrant as specified in its Charter) DELAWARE (State or other jurisdiction of incorporation) 000-20985 06-1226727 --------- ---------- Commission File No. I.R.S. Employer Identification 1265 Harbor Bay Parkway, Alameda, CA 94502 ----------- ----- Address of principal executive offices Zip Code (510) 749-5100 Registrant's telephone number, including area code ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE The Registrant (the Company) on June 24, 2003 elected to file a Form 10-QSB for the quarter ended March 31, 2003 as the Company qualifies as a small business filer in accordance with Regulation S-B and has elected to opt into the small business disclosure system. The financial results and disclosures appearing in the Form 10-QSB are identical to the results and disclosures appearing in the Company's previously-filed Form 10-Q for the quarter ended March 31, 2003. The Company intends to file all future periodic reports as a small business filer. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: Alameda, California June 24, 2003 CALYPTE BIOMEDICAL CORPORATION (Registrant) /s/ Richard D. Brounstein ---------------------------------- Richard D. Brounstein Executive Vice President and Chief Financial Officer